SanBio granted regenerative medicine advanced therapy designation from the U.S. FDA for SB623 for the treatment of chronic neurological motor deficits secondary to traumatic brain injury

19 September 2019 - The SanBio Group today announced that the U.S. FDA has granted regenerative medicine advanced therapy designation ...

Read more →

Immunotherapy a groundbreaking new cancer treatment, but prohibitively expensive

10 September 2019 - Dave Roberts is fighting for his life, and his doctor says there is only one option ...

Read more →

DiscGenics receives FDA fast track designation for disc degeneration cell therapy

26 August 2019 - DiscGenics today announced that the U.S. FDA has granted Fast Track designation for its investigational cell ...

Read more →

Cancer patient David Downs working to bring treatment that helped him to NZ

18 August 2019 - There are those people who cheerfully refer to themselves as glass half-full types – and then ...

Read more →

Trump Administration makes CAR T-Cell cancer therapy available to Medicare beneficiaries nationwide

7 August 2019 - Decision ensures consistency in access to the innovative new cancer therapy, and CMS is working closely ...

Read more →

ICER seeks public comment on proposed methods adaptations for assessments of potential cures and other transformative therapies

6 August 2019 - Proposed adaptations help manage increased uncertainty, capture new value dimensions for appraisal committee voting, and adopt a ...

Read more →

Melbourne to pioneer free treatment to save sickest cancer kids

4 August 2019 - The nation’s youngest cancer patients, who had previously been forced to travel overseas for lifesaving treatment, will ...

Read more →

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

30 July 2019 - Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by ...

Read more →

CAR T-cell therapy: a microcosm for the challenges ahead in Medicare

29 July 2019 - The search for more effective and less toxic therapies for cancer has occupied scientists for decades. ...

Read more →

Caladrius Biosciences receives advanced therapy medicinal product classification for CLBS12, its CD34+ cell therapy for critical limb ischaemia

15 July 2019 - Caladrius Biosciences announced today that the EMA has granted Advanced Therapy Medicinal Product classification to the Company’s ...

Read more →

Innovation prizes to support cell and gene therapy

2 July 2019 - Personalised cell and gene therapy represent a fundamental therapeutic revolution.  ...

Read more →

Health economic assessment of Kymriah in diffuse large B-cell lymphoma

20 June 2019 - TLV has produced a health economic knowledge base for county councils for CAR-T cell treatment Kymriah ...

Read more →

FDA grants fast track designation for Torque's first deep-primed T cell cancer immunotherapy program, TRQ-1501

18 June 2019 - Torque announced today that the U.S. FDA granted fast track designation for Torque's first Deep-Primed T cell ...

Read more →

Paying for CAR-T therapy amidst limited health system resources

3 June 2019 - CAR-T is paving a new path toward achieving access and reimbursement within limited health-system resources. How do ...

Read more →

Mesoblast initiates rolling submission of biologics license application to U.S. FDA for remestemcel-L in the treatment of acute graft versus host disease

30 May 2019 - Mesoblast today announced that it has filed the first component of a rolling submission for a biologics ...

Read more →